[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.216.242. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 908
Citations 0
Editorial
June 2016

Alemtuzumab and Multiple SclerosisAnother Note of Caution

Author Affiliations
  • 1Institute of Clinical Neuroimmunology, Biomedical Center and Klinikum Grosshadern, Munich, Germany
  • 2Munich Cluster of Systems Neurology (SyNergy), Munich, Germany
JAMA Neurol. 2016;73(6):637-638. doi:10.1001/jamaneurol.2016.0259

Alemtuzumab is a humanized monoclonal antibody that binds to CD52, a surface molecule expressed by many types of immune cells, including T lymphocytes, B lymphocytes, monocytes, macrophages, and eosinophils.13 After intravenous infusion, the therapeutic antibody binds to CD52-expressing cells in blood and to a lesser extent in lymphoid organs. Antibody binding is followed by profound depletion of CD52-positive immune cells brought about by complement- and cell-mediated cytotoxic mechanisms. Of all the immunotherapies currently available for multiple sclerosis, alemtuzumab has the longest lasting effects on the immune system.

First Page Preview View Large
First page PDF preview
First page PDF preview
×